If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
=== Mechanism of action === NET is a target for drugs, that are potent and selective or mixed NET inhibitors (e.g. atomoxetine and reboxetine), named NRI, have been successfully developed to treat various mental disorders, but unfortunately also drugs of abuse (e.g. cocaine). The NRI drugs used medically for mental disorders include attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, mood disorders, personality disorders, bipolar disorder, psychosexual disorders and schizophrenia. NRI drugs bind to the NET and inhibit the reuptake of NE. These drugs therefore increase the availability of NE for binding to postsynaptic receptors that regulate adrenergic neurotransmission. Selective NRIs blocks only the monoamine transporter NET, excluding the other two monoamine transporters (DAT and SERT) for dopamine and serotonin. Because if the NRI drug affects those other monoamine transporters they would be called nonselective inhibitors. However, the selectivity and mechanism of action for the NRI drugs remain unknown and, to date, only a very limited number of NRI-selective inhibitors are available. Research has shown that these new ligands vary both in the selectivity and potency at each of these three monoamine transporter sites (NET, DAT and SERT). However, those ligands may be of value in clarifying the pharmacological mechanisms, and in the discovery of new selective NRI drugs with fewer side effects.
=== Discovery === Copernicium was first created on 9 February 1996, at the Gesellschaft für Schwerionenforschung (GSI) in Darmstadt, Germany, by Sigurd Hofmann, Victor Ninov et al. This element was created by firing accelerated zinc-70 nuclei at a target made of lead-208 nuclei in a heavy ion accelerator. A single atom of copernicium was produced with a mass number of 277. (A second was originally reported, but was found to have been based on data fabricated by Ninov, and was thus retracted.)
==== Territories of the United States ==== Taco Bell operates several stores in Guam. Taco Bell operates one restaurant in the Northern Mariana Islands, located on the island of Saipan. In 2005 Taco Bell started the permitting process to set up a restaurant in American Samoa in Pago Pago. Taco Bell also operates stores in Puerto Rico.
== Maintenance == When maintaining the aquariums for this breed, instead of using substrate, breeders go for driftwood roots or branches, bark of Beech or oak and position them in a way that offers some kind of shades to the fish. To add to the natural environment, dry leaves are also used, which along with the Tannin from the wood, act as a supplement fish food when decomposed. For king bettas, always dim lighting and aquatic vegetation like Microsorum pteropus and Taxiphyllum barbieri is advised. A sprinkling of floating aquatic plants also help to maintain the lighting in the tank. An air-powered sponge filter in place of other forms of filtration gadgets are preferred. As these species tend to make jumps, the tank should be covered, but care should be taken not to fill it to the brim as the fish seek the humid air that develops in the empty space.
alpha-decay -> strong interaction, beta-decay -> weak interaction, gamma-decay -> electromagnetism. In alpha decay, a particle containing two protons and two neutrons, equivalent to a He nucleus, breaks out of the parent nucleus. The process represents a competition between the electromagnetic repulsion between the protons in the nucleus and attractive nuclear force, a residual of the strong interaction. The alpha particle is an especially strongly bound nucleus, helping it win the competition more often. However some nuclei break up or fission into larger particles and artificial nuclei decay with the emission of single protons, double protons, and other combinations. Beta decay transforms a neutron into proton or vice versa. When a neutron inside a parent nuclide decays to a proton, an electron, an anti-neutrino, and nuclide with higher atomic number results. When a proton in a parent nuclide transforms to a neutron, a positron, a neutrino, and nuclide with a lower atomic number results. These changes are a direct manifestation of the weak interaction. Gamma decay resembles other kinds of electromagnetic emission: it corresponds to transitions between an excited quantum state and lower energy state. Any of the particle decay mechanisms often leave the daughter in an excited state, which then decays via gamma emission. Other forms of decay include neutron emission, electron capture, internal conversion, cluster decay.
Sources: en.wikipedia.org
"Vitellogenin, juvenile hormone, insulin signaling, and queen honey bee longevity". Proceedings of the National Academy of Sciences. 104 (17): 7128–33. Bibcode:2007PNAS..104.7128C. doi:10.1073/pnas.0701909104. PMC 1852330. PMID 17438290.
Bromley is a large town in Greater London, England, within the London Borough of Bromley. It is 9+1⁄2 miles (15 kilometres) southeast of Charing Cross, and had an estimated population of 97,540 as of 2021. Originally part of Kent, Bromley became a market town, chartered in 1158. Its location on a coaching route and the opening of a railway station in 1858 were key to its development and the shift from an agrarian village to an urban town. As part of the growth of London's conurbation in the 20th century, Bromley Town significantly increased in population and was incorporated as a municipal borough in 1903 and became part of the London Borough of Bromley in 1965. Bromley today forms a major retail and commercial centre. It is identified in the London Plan as one of the 13 metropolitan centres of Greater London.
=== Anthropogenic influences === Anthropogenic industry unintentionally injects micronutrients into various ecosystems across the globe. The addition of micronutrients into ecosystems can have both positive and negative impacts. In the face of climate change, the fertilization of oceans with iron has been proposed as a method of carbon sequestration; however, elevated levels of iron in high nutrient, low chlorophyll regions of the ocean can cause the production of harmful algal blooms which are toxic to both humans and marine life. Similarly, in lakes, isolated seas, and coastal bays or gulfs, addition of micronutrients can cause eutrophication leading to hypoxia, decreasing ecosystem health. Micronutrients are released into ecosystems from many anthropogenic activities. Fossil fuel combustion releases micronutrients such as Zn, Fe, Ni, and Cu into the atmosphere, surrounding soils, and nearby waterways. Agricultural fertilizer runoff contains many micronutrients like Fe, Mn, Zn, Cu, Co, B, Mo and Ni. Fertilizer runoff injects these micronutrients into groundwater, soils, and waterways. Deforestation decreases soil compaction, resulting in increased aeolian transport of dust containing micronutrients, especially Fe. Industrial mining produces tailings which contaminates runoff. The improper treatment of mining tailings can result in the leakage of micronutrients into groundwater, soils, and nearby waterways.
Texts on Wikisource: Beck, Archibald Frank (1911). "Waterloo Campaign, 1815". Encyclopædia Britannica. Vol. 28 (11th ed.). pp. 371–381. Maude, Frederic Natusch (1911). "Napoleonic Campaigns". Encyclopædia Britannica. Vol. 19 (11th ed.). pp. 212–236. Robinson, Charles Walker (1911). "Peninsular War". Encyclopædia Britannica. Vol. 21 (11th ed.). pp. 90–98. Rose, John Holland (1911). "Napoleon I.". Encyclopædia Britannica. Vol. 19 (11th ed.). pp. 190–211. "A new scholarly journal in 2023: European Review of Studies on the Napoleonic and Restoration Periods" The Legend of Bonaparte The Napoleonic Wars Exhibition held by The European Library 15th Kings Light Dragoons (Hussars) Re-enactment Regiment 2nd Bt. 95th Rifles Reenactment and Living History Society The Napoleonic Wars Collection Website Napoleon, His Army and Enemies Napoleonic Guide War and Peace by Leo Tolstoy at Project Gutenberg Napoleonic Wars Fondation Napoléon The Napoleon Series
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.